Materials managers often seek to streamline inventory by reducing separate vials. A fixed peptide blend can appear tidy: one product, one label, one purchase-order line. Yet when a batch is being booked into stores, a supplier may refuse to sell a fixed blend even if the individual compounds are available. The refusal is rarely arbitrary. It usually reflects batch-level documentation, compliance obligations and the practical limits of analytical verification for research-use-only materials. For laboratories working under controlled in-vitro conditions, understanding these reasons helps avoid delays and keeps every vial traceable to a valid certificate.
Batch Traceability and the Limits of a Single Certificate of Analysis
Why a Blend Cannot Inherit Individual CoAs
When a batch is booked into stores, each vial is linked to a batch-specific certificate of analysis. The shop’s published statements describe batch-level analytical verification supporting purity, identity and contaminant screening, with a CoA for every product. If a supplier were to combine two peptides into a single fixed blend, the original CoAs for the individual components would no longer cover the final article. The blend would become a new material requiring its own identity, purity, homogeneity and contaminant testing. Many suppliers do not hold validated methods for every possible combination, and they may decline rather than issue a certificate that does not match the contents of the vial. This is especially important for research-use-only materials, where the CoA is the primary record of what the batch contains and how it was tested. The published catalogue at Peptides uk lists individual entries such as Ipamorelin 5mg and CJC-1295 (No DAC) 5mg, each with its own batch documentation; fixed blends are not listed. The shop’s FAQ states that it does not supply blended peptides and recommends combining only within a controlled experimental design.
The Internal Test Reference and Batch-Level Documentation
Restocked products may carry the same Internal Test Reference as earlier stock. The ITR links to associated sample testing reports, but it does not confirm that separate deliveries come from the same production lot or have had separate independent testing. For a fixed blend, the ITR would need to reference testing of the blend itself, not simply the components. If the batch is being allocated to stores, the supplier cannot assign a valid ITR to an untested blend without undermining the batch records. Vial labels combine a SKU code and an expiry date, for example BPC10-03/27, and link to the corresponding CoA. A blend would require a new SKU, a new label reference and a new certificate. Rather than create a reference that cannot be supported by batch-level testing, a supplier may refuse the request. This protects the documentation chain and helps researchers quote the correct reference for a specific batch.
Compliance, Intended Use, and the Risk of Misbranding
Research-Use-Only Status and Refusal of Non-Compliant Orders
All products are strictly for controlled laboratory and analytical research. They are not medicines, medical devices, injectables, treatments or food supplements under UK law, and they are not supplied for therapeutic, clinical or diagnostic purposes. The shop’s published position is that materials are not for human or veterinary use, consumption, administration or clinical application. The About page states that orders inconsistent with compliance standards may be refused. A fixed blend can increase the risk of misbranding because it may be perceived as a combined product intended for administration rather than separate research reagents. Suppliers may therefore refuse to sell a blend when a batch is being booked into stores, especially if the request implies a use outside controlled in-vitro work. The shop does not provide therapeutic, medical, performance, injection, ingestion or dosing guidance, and it recommends buying peptides individually and combining only within a controlled experimental design.
Labelling and the Problem of a Single Blend Reference
Products are labelled “For Research Use Only – Not for Human Consumption”, in line with the shop’s stated position on MHRA guidance. A fixed blend would require its own label, its own expiry reference and its own CoA. If the supplier has not tested the blend, it cannot issue a label that truthfully links to a batch certificate. Misbranding risk arises when a single blend reference implies a combined identity that has not been analytically verified. The shop’s current published wording lists CoAs Janoshik Analytical Reports and ≥99% verified purity; these figures should be reconfirmed on the live site and on the batch CoA for the specific product. For a blend, the researcher would need a new CoA, not a reference to the individual components. Suppliers may refuse to create that reference when booking a batch into stores because it would sit outside the established catalogue and documentation framework. Materials managers should retain individual vials and record batch references separately.
Stability, Homogeneity, and Practical Laboratory Constraints
Storage Profiles and Freeze–Thaw Risks
Lyophilised peptides are typically stored at –20°C or below, sealed with desiccant, and protected from moisture, heat and light. Different peptides may have different stability profiles, and a fixed blend cannot be separated once mixed. Even in lyophilised powder, combining two peptides may not yield a uniform distribution; particle size, density and mannitol content can vary. Trace amounts of mannitol are present in the shop’s peptides, and blending could affect solubility and stability during storage. Reconstituted peptides are less stable and should be stored at 2–8°C for short-term laboratory use, with repeated freeze–thaw cycles avoided. A supplier may refuse to blend when a batch is being booked into stores because it cannot guarantee that the blend remains homogeneous and stable across the batch’s shelf life. For in-vitro workflows, keeping components separate allows the researcher to control diluent volume and concentration for each assay and to document each component’s contribution.
Controlled Experimental Design Requires Separate Components
A fixed blend locks the ratio of components, which may not suit controlled experimental design. Researchers often need to vary the concentration of one component while holding another constant, or to prepare separate stock solutions for an in-vitro assay. The shop’s FAQ recommends buying peptides individually and combining only within a controlled experimental design. A supplier may refuse a fixed blend when booking a batch into stores because the blend would not support that level of experimental control. The free reconstitution calculator described on product pages and in the FAQs is for laboratory research use only; it must not be used for human or veterinary dosing. Materials managers should maintain separate vials, record the diluent volume and final concentration for each in-vitro experiment, and repeat that these materials are not for human or veterinary use. This supports reproducibility and keeps every step within the research-use-only framework.
